[Form 4] Amneal Pharmaceuticals, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Nikita Shah, Executive Vice President of Amneal Pharmaceuticals, Inc. (AMRX), reported the sale of 71,694 shares of Class A common stock on 08/14/2025 at a weighted-average price of $9.29 per share, with individual trade prices ranging from $9.16 to $9.41. After the reported dispositions, the reporting person beneficially owned 267,235 shares, held directly. The Form 4 was filed indicating the transaction type as a sale and includes an explanatory footnote that the reported price is a weighted average from multiple trades. The form is signed by an attorney-in-fact on 08/15/2025.

Positive

• Timely disclosure: Form 4 lists the transaction date 08/14/2025 and includes a filed signature dated 08/15/2025, indicating prompt reporting.
• Complete pricing disclosure: The filing provides a weighted-average price and a stated price range ($9.16 to $9.41) with an offer to provide per-trade details on request.

Negative

• Insider disposition: Reporting person sold 71,694 shares, reducing direct beneficial ownership to 267,235 shares.
• No stated reason for sale: The filing does not include context such as a Rule 10b5-1 plan or purpose for the sale.

Insights

Securities Analyst

TL;DR: Insider sold 71,694 shares at a weighted-average $9.29, leaving 267,235 shares; disclosure appears timely and complete.

The filing documents a direct sale of 71,694 Class A shares on 08/14/2025 at a weighted-average price of $9.29, with trades between $9.16 and $9.41. The report shows 267,235 shares beneficially owned after the sale. From a reporting perspective, the Form 4 provides the required transaction details and a footnote explaining the weighted-average price and availability of trade-level details upon request. There are no derivative transactions reported. This is a routine Section 16 disclosure of an insider sale; the filing itself does not provide motive, planned use of proceeds, or other context.

Corporate Governance Expert

TL;DR: Form 4 properly discloses an insider disposition; signatures and explanatory footnote meet common compliance norms.

The statement identifies the reporting person as Executive Vice President and indicates a direct ownership form after the sale. The explanatory footnote discloses that the price is a weighted average across multiple transactions and offers to provide detailed pricing information to the company or SEC staff on request. The signature by an attorney-in-fact is dated the day after the transaction, which aligns with timely filing expectations. The document contains no indications of option exercises, grants, or derivative activity.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shah Nikita

(Last) (First) (Middle)

C/O AMNEAL PHARMACEUTICALS, INC.

400 CROSSING BLVD.

(Street)

BRIDGEWATER NJ 08807

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Amneal Pharmaceuticals, Inc. [ AMRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Executive Vice President

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	08/14/2025		S		71,694	D	$9.29(1)	267,235	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price included in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.16 to $9.41 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Remarks:

	/s/ Denis Butkovic, Attorney-in-Fact	08/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Amneal (AMRX) insider Nikita Shah do on 08/14/2025?

Nikita Shah sold 71,694 shares of Class A common stock on 08/14/2025, as reported on the Form 4.

At what price were the AMRX shares sold?

Weighted-average price $9.29 per share, with individual trade prices ranging from $9.16 to $9.41.

How many AMRX shares does the reporting person own after the sale?

267,235 shares beneficially owned following the reported transaction.

Was the Form 4 filed promptly for the AMRX transaction?

Yes. The transaction occurred on 08/14/2025 and the Form 4 is signed and dated 08/15/2025.

Does the filing show any derivative transactions or option exercises?

No. Table II (derivatives) contains no reported transactions; only a non-derivative sale is reported.